Indication: Cancer

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination with Nivolumab, an anti-PD-1 antibody, for Subjects with HER2-expressing Advanced Breast and Urothelial Cancer

HER2-expressing Advanced Breast/Urothelial Cancer

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Daiichi Sankyo Company, Limited

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.